Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20344)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Primary Target | Pathway | GR50 | GRmax | GR_AOC | Death_AUC | GR Hill Coefficient | GEC50 | GR r2 |
---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-453 | Doxorubicin | Chemo | Chemotherapy | 0.0058313 | -0.3476 | 0.7915 | 0.1805 | 1.7510 | 0.0071438 | 0.98132 |
MDA-MB-453 | Taxol | Chemo | Chemotherapy | 0.002374 | 0.0356 | 0.6674 | 0.1683 | 1.2620 | 0.0023576 | 0.81734 |
MDA-MB-453 | Topotecan | Topo I | Chemotherapy | 0.0066897 | -0.5289 | 0.9258 | 0.1604 | 1.0131 | 0.010358 | 0.92364 |
MDA-MB-453 | Etoposide | Topo II | Chemotherapy | 0.38265 | -0.0601 | 0.3658 | 0.0418 | 1.5864 | 0.41689 | 0.99692 |
MDA-MB-453 | Dasatinib | BCR/ABL | MAPK/nRTK | 11.2977 | 0.5486 | 0.0776 | 0.0229 | 1.2179 | 27.8439 | 0.76835 |
MDA-MB-453 | Trametinib | MEK | MAPK/nRTK | 0.034423 | 0.0489 | 0.3253 | 0.0542 | 1.5373 | 0.031553 | 0.98454 |
MDA-MB-453 | Saracatinib | SRC | MAPK/nRTK | 8.3734 | 0.3925 | 0.0634 | 0.0273 | 1.5016 | 17.4019 | 0.95549 |
MDA-MB-453 | ABT-737 | Bcl2/XL | Misc | 5.9702 | 0.1516 | 0.0227 | 0.0377 | 4.9881 | 5.7097 | 0.9783 |
MDA-MB-453 | Vorinostat | HDAC | Misc | 0.9215 | -0.6076 | 0.3291 | 0.1421 | 3.3225 | 1.1628 | 0.99512 |
MDA-MB-453 | Luminespib | HSP90 | Misc | 0.0032643 | -0.4995 | 0.8803 | 0.2734 | 2.6468 | 0.0042685 | 0.99671 |
MDA-MB-453 | A-1210477 | Mcl-1 | Misc | Inf | 0.9330 | -0.0364 | 0.0157 | 0.0000 | Inf | -0.33803 |
MDA-MB-453 | Olaparib | PARP | Misc | 1.6695 | -0.0358 | 0.2414 | 0.0284 | 0.7989 | 4.3612 | 0.99257 |
MDA-MB-453 | Bleomycin | Radiation | Misc | 1.3087 | 0.0154 | 0.2124 | 0.0259 | 1.2776 | 1.4452 | 0.99022 |
MDA-MB-453 | Ipatasertib | AKT | PI3K/mTOR | 0.53911 | -0.1551 | 0.3144 | 0.0753 | 1.3090 | 0.65666 | 0.98992 |
MDA-MB-453 | Alpelisib | PI3Ka | PI3K/mTOR | 0.53182 | -0.3068 | 0.3532 | 0.0861 | 0.7133 | 1.648 | 0.979 |
MDA-MB-453 | Taselisib | PI3Ka, g, d | PI3K/mTOR | 0.0034639 | -0.6347 | 1.0079 | 0.2403 | 0.8199 | 0.0064512 | 0.90769 |
MDA-MB-453 | TGX221 | PI3Kb | PI3K/mTOR | 15.3342 | 0.8281 | -0.0281 | 0.0177 | 4.9457 | 12.4514 | 0.62788 |
MDA-MB-453 | Torin2 | mTOR/ATM/ATR | PI3K/mTOR | 0.0083807 | -0.8141 | 0.6934 | 0.2249 | 0.9084 | 0.023455 | 0.98046 |
MDA-MB-453 | Everolimus | mTOR1 | PI3K/mTOR | Inf | 0.0309 | 0.8879 | 0.1169 | 0.0000 | Inf | 0.43273 |
MDA-MB-453 | INK-128 | mTORC1/2 | PI3K/mTOR | 0.009907 | -0.4684 | 0.7631 | 0.1914 | 1.6470 | 0.01349 | 0.98649 |
MDA-MB-453 | PF-4708671 | p70S6K | PI3K/mTOR | 4.291 | 0.0482 | 0.0418 | 0.0294 | 4.9998 | 4.2285 | 0.98022 |
MDA-MB-453 | Buparlisib | pan PI3K | PI3K/mTOR | 0.69073 | -0.6073 | 0.3442 | 0.1124 | 1.2215 | 1.4247 | 0.9883 |
MDA-MB-453 | Pictilisib | pan PI3K | PI3K/mTOR | 0.45409 | -0.3736 | 0.3924 | 0.0999 | 0.7355 | 1.4609 | 0.99053 |
MDA-MB-453 | Ceritinib | ALK | RTK | 0.36617 | -0.6866 | 0.4840 | 0.1577 | 1.1705 | 0.84209 | 0.99139 |
MDA-MB-453 | Neratinib | EGFR/HER2 | RTK | 0.036055 | -0.3216 | 0.5532 | 0.1255 | 0.4562 | 0.2347 | 0.98118 |